Synchronous Ovarian and Endometrial Cancer—an International Multicenter Case-Control Study

Abstract

Prognosis of patients with SEOC tended to be the same in comparison with matched controls with either one EC or OC. Therefore, it could be considered that patients with SEOC may be eligible for clinical trials of the advanced tumor component if no additional therapy is indicated for the other component.

Does synchronous endometrioid endometrial cancer have any prognostic effect on Stage I endometrioid ovarian cancer?

“…However, this study does not support this finding; following adjustment for histological type and stage, the prognosis was not remarkably different between SEOC and EOC in the early stages. This is in agreement with the results of an international multicentric case-control study [19].…”

“…Therefore, no genetic testing was performed. As indicated in many studies, it is unlikely that patients with synchronous primary cancers have hereditary cancer syndromes [19,26,27].…”

Clinicopathological Characteristics and Prognostic Factors of Synchronous Endometrial and Ovarian Cancers—A Single-Institute Review of 43 Cases

“…An international multicenter study has suggested that adjuvant treatment recommendations for SCEO should consider the risk of relapse of individual tumor component, and carboplatin and paclitaxel should be used as CT regimen, and if the endometrial component of SCEO is advanced, radiation therapy should be given subsequently to CT. 22 Chiang et al 13 found no significant impact of adjuvant therapy on survival on patients with SCEO. However, Ayhan et al 18 suggested that adjuvant therapy should be given to patients with SCEO to improve survival.…”

Synchronous Primary Cancers of the Endometrium and Ovary With the Same Histopathologic Type Versus Endometrial Cancer With Ovarian Metastasis

“…2,18,21 In an international multicenter study after adjusting factors that might influence survival such as age, disease stage, histology, tumor grade, and residual tumor after surgery, 77 patients with SCEO, 132 patients with primary endometrial cancer, and 126 patients with primary ovarian cancer were compared, and results showed that 5-year OS rates did not differ between groups (71.6%, 79.8%, and 69.3%, respectively). 22 They suggested that postoperative treatment recommendations for SCEO should consider the risk of relapse of the respective tumor compound, and carboplatin and paclitaxel should be used as CT regimen. 22 They also suggested if an endometrial component of the SCEO is advanced, then RT could be given subsequently to CT. 22 A population-based assessment of more than 1500 patients with SCEO showed that younger age at diagnosis, earlier stage, and better grade of disease are favorable characteristics.…”

“…22 They suggested that postoperative treatment recommendations for SCEO should consider the risk of relapse of the respective tumor compound, and carboplatin and paclitaxel should be used as CT regimen. 22 They also suggested if an endometrial component of the SCEO is advanced, then RT could be given subsequently to CT. 22 A population-based assessment of more than 1500 patients with SCEO showed that younger age at diagnosis, earlier stage, and better grade of disease are favorable characteristics. 23 In our study, age younger than 55 years, premenopausal status, performing lymphadenectomy, absence of omental metastasis, and absence of residual disease were found to be significant prognostic factors in univariate analysis (Table 5).…”